



# FILE COPY

July 8, 2004

John M. Baldoni, Ph.D.  
David M. Cocchetto, Ph.D.  
GlaxoSmithKline Research & Development  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398

Dear Dr. Baldoni and Dr. Cocchetto:

Your petition requesting the Food and Drug Administration to refrain from approving any ANDA for a topical mupirocin calcium product containing the amorphous form of the active ingredient was received by this office on 07/08/2004. It was assigned docket number 2004P-0290/CP 1 and it was filed on 07/08/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in black ink, appearing to read "Lyle D. Jaffe".

Lyle D. Jaffe  
Division of Dockets Management  
Office of Management Programs  
Office of Management

2004P-0290

ACK 1